Randomized trial to evaluate the renoprotective effect of cilostazol on chronic kidney disease patients with arteriosclerosis obliterans

Randomized trial to evaluate the renoprotective effect of cilostazol on chronic kidney disease patients with arteriosclerosis obliterans - Cilostazol for chronic kidney disease with arteriosclerosis obliterans: randomized trial(CCKDA trial)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000527

Enrollment

Registered

2006-11-22

Start date

2006-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

Cilostazol 100mg and Aspirin 100mg daily Aspirin 100mg daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic kidney disease patients (CKD stage 2-4) with arteriosclerosis obriterans

Exclusion criteria

Exclusion criteria: Patients with allergy for cilostazol or aspirin, bleeding tendency, or pregnancy. Patients with other platelet aggregation inhibitor or anticoagulant drug. Patients who are inadequate to entry this study by physicians in charge.

Design outcomes

Primary

Measure	Time frame
Change in glomerular filtration rate and renal plasma flow	—

Secondary

Measure	Time frame
Change in pulse wave velocity and von Willebrand factor Occurrence of cardiovascular event	—

Countries

Japan

Contacts

Public ContactChie Saito

Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences,University of Tsukub Division of Nephrology

kidney@md.tsukuba.ac.jp029-853-3202

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026